GENE ONLINE|News &
Opinion
Blog

2020-09-06| M&A

Encouraging Performance of Cardiovascular Drug Vindicates Novartis’ $9.7 Billion Buyout Deal

by Rajaneesh K. Gopinath
Share To

By Pavel Ryzhov, Ph.D.

Heart disease is the leading cause of death in the United States [1]. Among the types of heart disease, one of the most prevalent is atherosclerotic cardiovascular disease (ASCVD). It is caused by the gradual buildup of fats and cholesterol on the walls of blood vessels and the resulting deposition of clogging plaques. Low-density lipoprotein cholesterol (LDL-C) is the primary contributor to that process, and associated hyperlipidemia is, therefore, a critical underlying condition that can contribute to complications such as heart attack or a stroke [2].

The current treatment landscape already includes the administration of potent LDL-C reducing medicines such as statins. However, further lowering of LDL-C with novel types of treatments and searching for better patient adherence results is the focus of recent efforts by Novartis.

In a recent press-release [3], results were announced for two Phase III trials (ORION-10 and ORION-11), which evaluated patient responses to first-in-class LDL-C reduction medicine, inclisiran. Both were placebo-controlled, double-blind, and randomized trials that aimed to investigate the safety, efficacy, and tolerability of the treatment in patients with ASCVD, high LDL-C, and already receiving maximum doses of LDL-C lowering medicines like statin or ezetimibe. With 1561 and 1617 enrolled patients, and trials conducted at 145 sites in the US and 70 sites in seven countries in ORION-10 and ORION-11, respectively, they both met their primary endpoints.

Specifically, mean placebo-adjusted percentage change in LDL-C reduction was 52% (p<0.0001) and 50% (p<0.0001) at 17 months and demonstrated time-adjusted percentage change in LDL-C reduction was 54% (p<0.0001) and 49% (p<0.0001) from 3 to 18 months. The data from both studies were published online [4].

Results from the trials also showed low inter-individual variability, where almost 100% of treated patients showed over 30% reduction of LDL-C levels when adjusted to the placebo. Besides, the tolerability and safety profile of inclisiran was comparable to the placebo. According to David Soergel, Novartis’s Global Head of Cardiovascular, Renal and Metabolic Drug Development, the post-hoc analysis of the trials’ results “reinforced [their] view of inclisiran’s therapeutic value and its potential as the first cholesterol-lowering siRNA.”

Inclisiran is a double-stranded small interfering RNA (siRNA) that can be uptaken by hepatocytes, where it can increase LDL-C receptor expression on the cell surface and, thus, lower LDL-C levels in the blood. It does so by blocking the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme. Binding of the enzyme to the receptor prevents it from the expression on the cell surface due to sequestering in the lysosome [5].

Thus, RNA interference with inclisiran would decrease the available pool of PCSK9 and increase LDL-C receptor numbers. Inclisiran is administered as a subcutaneous injection that is followed up after 3 months and every 6 months after that. Novartis previously added inclisiran to its R&D pipeline by acquiring The Medicines Company in 2019.

With the positive results from the trials, Novartis is expecting to receive the response from FDA and EMA, where inclisiran is currently under review for the treatment of primary hyperlipidemia in adults with high LDL-C on maximally tolerated doses of statins.

Editor: Rajaneesh K. Gopinath, Ph.D.

Related Article: MyoKardia Announces Positive Topline Results for Targeted Cardiomyopathy Drug

References
  1. https://www.novartis.com/news/media-releases/novartis-new-analysis-shows-high-consistency-lowering-ldl-c-individual-response-investigational-inclisiran

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
These Pharma Companies Are Laying Off Employees Due to Restructuring
2022-06-30
Novartis’s Lung Cancer Drug Approved for Marketing in Europe
2022-06-23
LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top